Researchers ‘trick’ body into accepting organ transplant using cancer tactic
Friday, March 27, 2020
Researchers at the University of Pittsburgh have developed technology designed to "trick" the body into accepting a transplanted organ.
"It's like hacking into the immune system, borrowing a strategy used by one of humanity's worst enemies to trick the body into accepting a transplant," said senior author Steven Little of the Swanson School of Engineering at Pitt. "And we do it synthetically."
The enemy Little is referring to is cancer, which tricks the body's immune system into thinking the tumor is a part of the body. His research team injected rats with cell-sized micro particles twice after some sort of graft surgery.
Some rats had an entire hind leg grafted to their bodies. The treated animals were followed for approximately 200 days. Six of eight animals accepted the grafts in a time period that equates to 30 human years. Control animals received immunosuppressive therapy and each rejected grafts within three weeks of the drug therapy being stopped.
Each successful animal's graft was biopsied. Tissue architecture remained intact and appeared similar to muscle and skin biopsied taken from normal animals. Even with an increased number of Treg cells, the grafted rats' immune system remained intact.
Cancer tumors can evade the body's immune system by secreting the protein CCL22. The micro particle system is capable of generating and sustaining a gradient of CCL22 from the site of micro particle placement. The micro particles release CCL22, which draws regulatory T-cells (Tregs) to graft site. Once there, the T-cells tell the immune system that the graft is part of the body and therefore safe. That allows the graft to evade an attack by the body's immune system.
A paper outlining the treatment was published on March 13 in Science Advances.
The biggest issue facing organ transplantation is graft rejection. With mounting evidence showing involvement by Tregs in organ retention, researchers have sought ways to limit the power of these cells without relying on immunosuppressive medications.
"These drugs hammer the immune system into submission so it can't attack the transplanted organ, but then it can't protect the body either," said coauthor Stephen Balmert, a postdoctoral researcher in the Pitt School of Medicine. "We're trying to teach the immune system to tolerate the limb, so that a transplant recipient can remain immunocompetent."
The micro particle treatment protocol becomes much easier than relying on cell-based therapies which are currently be studied. Immunosuppressive drug therapy, the standard way doctors have combated organ rejection, leaves patients with a weakened immune system and vulnerable infectious diseases, cancer, diabetes and other illnesses.
"The ability to induce transplant tolerance while avoiding systemic immunosuppression, as demonstrated in these innovative studies, is especially important in the context of vascularized composite transplantation where patients receive quality-of-life transplants, such as those of hands or face," said co-author Angus Thomson of the Thomas E. Starzl Transplantation Institute at Pitt.
The treatment method is still a long way off from being used in humans. The research team will next study the method in pigs as a way to determine dosing levels for human trials.
- Best exercises for gluteus medius strengthening
- Breaking down barriers to make career and technical pathways accessible for everyone
- Pectoralis minor: Far from a minor problem
- The importance of hip internal rotation
- Millions of high school students set for success: Celebrating Career and Technical Education Month
- To fight crime, engage kids in quality after-school programs
- You can’t be what you can’t see
- Study: Researchers search for better ways to nix inventory errors
- To know or not to know, that is the question
- How NGOs help improve global education
- 6 effective video marketing tactics for the new year
- Pull up, terrain ahead
- Should your dental practice offer membership plans?
See your work in future editions
Your content, Your Expertise,
Your Industry Needs YOUR Expert Voice & We've got the platform you needFind Out How